Phathom Pharmaceuticals Inc (PHAT) Stock: Analyzing the Market Value
The 36-month beta value for PHAT is at 0.01. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2
The 36-month beta value for PHAT is at 0.01. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2
Xeris Biopharma Holdings Inc (NASDAQ: XERS) has seen a decline in its stock price by -2.96 in relation to its previous close of 4.90. However,
The stock of Cannae Holdings Inc (CNNE) has seen a 1.11% increase in the past week, with a 3.36% gain in the past month, and
Summit Therapeutics Inc (NASDAQ: SMMT)’s stock price has gone decline by -3.34 in comparison to its previous close of 24.61, however, the company has experienced
The stock of Main Street Capital Corporation (MAIN) has gone down by -2.10% for the week, with a -1.58% drop in the past month and
The stock has a 36-month beta value of 0.79. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as
The stock of EHang Holdings Ltd ADR (NASDAQ: EH) has increased by 3.27 when compared to last closing price of 19.24. Despite this, the company
In the past week, SLNH stock has gone up by 29.17%, with a monthly gain of 45.23% and a quarterly plunge of -45.52%. The volatility
The 36-month beta value for MRSN is also noteworthy at 0.84. There are mixed opinions on the stock, with 8 analysts rating it as a
© 2024, Powered by Smart TechOne